Altimmune to host key opinion leader call with dr. stephen harrison on pemvidutide phase 1 clinical trial results on september 30, 2021

Gaithersburg, md., sept. 29, 2021 (globe newswire) -- altimmune, inc. (nasdaq: alt), a clinical-stage biopharmaceutical company, today announced that it will host a key opinion leader (kol) call on its 12-week phase 1 clinical trial of pemvidutide (proposed inn, formerly known as alt-801) in overweight and obese subjects on thursday, september 30, 2021 at 9:00 am est.
ALT Ratings Summary
ALT Quant Ranking